Rigel Pharmaceuticals, Inc.  

(Public, NASDAQ:RIGL)   Watch this stock  
Find more results for Gary D. Maynard
3.16
+0.09 (2.93%)
Aug 4 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.06 - 3.20
52 week 1.56 - 5.20
Open 3.08
Vol / Avg. 317,955.00/496,951.00
Mkt cap 270.60M
P/E     -
Div/yield     -
EPS -0.99
Shares 88.14M
Beta 1.33
Inst. own 89%
Aug 4, 2015
Q2 2015 Rigel Pharmaceuticals Inc Earnings Call - Webcast
Aug 4, 2015
Q2 2015 Rigel Pharmaceuticals Inc Earnings Release
Jun 3, 2015
Rigel Pharmaceuticals Inc at Jefferies Global Healthcare Conference
May 7, 2015
Q1 2015 Rigel Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -835.31% -1101.91%
Operating margin -837.51% -1106.05%
EBITD margin - -964.70%
Return on average assets -45.63% -47.82%
Return on average equity -60.71% -54.03%
Employees 127 -
CDP Score - -

Address

1180 Veterans Blvd
SOUTH SAN FRANCISCO, CA 94080-1985
United States - Map
+1-650-6241100 (Phone)
+1-650-6241101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. It has various product candidates in development: fostamatinib; R348; two oncology product candidates, and two preclinical programs. Fostamatinib is an oral spleen tyrosine kinase (SYK) inhibitor. R348 is a topical janus kinase (JAK)/SYK inhibitor. It is conducting research in the disease areas of inflammation/immunology and muscle wasting/muscle endurance.

Officers and directors

Raul R. Rodriguez President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ryan D. Maynard Chief Financial Officer and Executive Vice President
Age: 45
Bio & Compensation  - Reuters
Dolly A. Vance Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Donald G. Payan M.D. Executive Vice President, President - Discovery and Research, Director
Age: 66
Bio & Compensation  - Reuters
Elliott B. Grossbard M.D. Executive Vice President and Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Keith A. Katkin Director
Age: 43
Bio & Compensation  - Reuters
Bradford S. Goodwin Independent Director
Age: 60
Bio & Compensation  - Reuters
Gary A. Lyons Independent Director
Age: 64
Bio & Compensation  - Reuters
Walter H. Moos Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Peter S. Ringrose Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters